Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial.

Lancet Respir Med · 2022 · PMC9635892 · PMID 36228641

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

Results were consistent for primary and secondary outcomes and there was no suggestion of benefit in any of the prespecified subgroups except for a nominally significant interaction for diabetes which is almost certainly the play of chance.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.